Generic pharma company Strides Pharma Science has reported a fivefold jump in its the net profit for the fourth quarter ended March 2025, driven by robust growth in US business and improved operating margins.
The operational PAT rose to Rs 113 crore in Q4FY25 from Rs 24.2 crore a year earlier, while the revenue climbed by 17% YoY to Rs 1190.4 crore. EBITDA grew 22% on year to Rs 218 crore, with margins expanding 75 basis points to 18.3%.
The company’s US revenue surged 23.2% YoY to $77 million, supported by new product launches and a stable base business.
For the full year FY25, net profit soared 12x to Rs 345 crore, with revenue up 17.2% at Rs 4565.3 crore. EBITDA for the year rose 36.8% to Rs 802.8 crore, and the EBITDA margin improved by 252 basis points to 17.6%.
Strides also reduced its net debt by Rs 512.8 crore, bringing the net debt-to-EBITDA ratio down to 1.9x. The board recommended a dividend of Rs 4 per share for FY25.
“We exceeded all key performance metrics for FY25, driven by strong execution in the US market and improved operational efficiency post-demerger,” said Arun Kumar, Founder & Non-Executive Chairperson, and Badree Komandur, MD & Group CEO.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
